Showing results (321-330 of 348) with videos related to

Sort By:
Pageof 35
Leukemia|April 16, 2014
Gene expression profile alone is inadequate in predicting complete response in multiple myelomaS B Amin, W-K Yip, S Minvielle, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|September 16, 2018
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Leukemia|June 24, 2017
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Plant Biotechnology Journal|December 2, 2017
Provitamin A biofortification of cassava enhances shelf life but reduces dry matter content of storage roots due to altered carbon partitioning into starchGetu Beyene, Felix R Solomon, Raj D Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trialA K Stewart, R Vescio, G Schiller, et al.
Bone Marrow Transplantation|February 16, 2000
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patientsR A Vescio, C H Wu, L Zheng, et al.
Cell Death & Disease|November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1N Amodio, M T Di Martino, U Foresta, et al.
Leukemia|January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyJ F San-Miguel, P G Richardson, P Sonneveld, et al.
Leukemia|April 18, 2006
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivoT A Navas, A N Nguyen, T Hideshima, et al.
Pageof 35